FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   BAUM MARK L 2. Date of Event Requiring Statement (Month/Day/Year) 12/12/2011 3. Issuer Name and Ticker or Trading Symbol Imprimis Pharmaceuticals, Inc. [IMMY] (Last) (First) (Middle) C/O IMPRIMIS PHARMACEUTICALS, INC., 437 SOUTH HIGHWAY 101, SUITE 209 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) SOLANA BEACH, CA 92075 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 8,240,045 I DermaStar International, LLC (1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock	02/28/2012	02/28/2012	Common Stock	7,498,500	$ 0.0017	I	DermaStar International, LLC (2)
Option (Right to Buy)	02/28/2012(3)	01/24/2022	Common Stock	625,000	$ 0.48	D	Â
Option (Right to Buy)	04/01/2012(4)	03/31/2017	Common Stock	300,000	$ 0.9	D	Â
Option (Right to Buy)	04/01/2012(5)	03/31/2017	Common Stock	125,000	$ 0.9	D	Â
Warrants	04/30/2012	04/29/2015	Common Stock	241,308	$ 1.185	I	DermaStar International, LLC (6)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
BAUM MARK L C/O IMPRIMIS PHARMACEUTICALS, INC. 437 SOUTH HIGHWAY 101, SUITE 209 SOLANA BEACH, CA 92075	  X	  X	  Chief Executive Officer	Â

Signatures

Mark L. Baum		04/27/2012
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	DermaStar International, LLC ("DermaStar") is the direct beneficial owner of 8,240,045 shares of the Issuer's Common Stock. Mr. Baum is a managing member of DermaStar and holds an ownership interest in DermaStar and may be deemed to have voting and dispositive power over the 8,240,045 shares of Common Stock owned by DermaStar. Mr. Baum disclaims beneficial ownership over such shares.
(2)	DermaStar is the direct beneficial owner of 10 shares of the Issuer's Series A Convertible Preferred Stock (the "Series A Preferred"). The Series A Preferred are convertible into a total of 7,498,500 shares of Common Stock. Mr. Baum is a managing member of DermaStar and holds an ownership interest in DermaStar and may be deemed to have voting and dispositive power over the 7,498,500 shares of Common Stock underlying the Series A Preferred owned by DermaStar. Mr. Baum disclaims beneficial ownership over such shares.
(3)	The stock options, granted on January 25, 2012 and effective as of February 28, 2012, were granted pursuant to the Issuer's 2007 Stock Incentive and Awards Plan. Mr. Baum's options vest over a 1 year period at a strike price of $0.48, with 1/12 of the total number of options vesting each monthly period following the grant date of the issuance of such options. As of the date of this Form 3 filing, options to purchase 260,417 shares of the Issuer's common stock are exercisable, but no options have been exercised.
(4)	The stock options, granted on April 1, 2012, were granted pursuant to the Issuer's 2007 Stock Incentive and Awards Plan. Mr. Baum's options vest over a 1 year period at a strike price of $0.90, with 75,000 options vesting immediately upon issuance, and an additional 9,375 options vesting monthly for the next twenty four months thereafter. As of the date of this Form 3 filing, options to purchase 93,750 shares of the Issuer's common stock are exercisable, but no options have been exercised.
(5)	The stock options, granted on April 1, 2012, were granted pursuant to the Issuer's 2007 Stock Incentive and Awards Plan. Mr. Baum's options maintain a strike price of $0.90, and vest quarterly over a one year term with the initial 31,250 options vesting on June 30, 2012, the next 31,250 options vesting on September 30, 2012, the next 31,250 options vesting on December 31, 2012 and the final 31,250 options vesting on March 31, 2013.
(6)	DermaStar is the direct beneficial owner of warrants to purchase up to 241,308 shares of the Issuer's Common Stock at an exercise price of $1.185 (the "Warrants"). The Warrants expire on the third anniversary of the issuance date. Mr. Baum is a managing member of DermaStar and holds an ownership interest in DermaStar and may be deemed to have voting and dispositive power of the Warrants and 241,308 shares of Common Stock underlying the Warrants owned by DermaStar. Mr. Baum disclaims beneficial ownership over such shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.